BackNovo Nordisk A/S Class B Overview

Novo Nordisk A/S Class B Cost of Revenue

Cost of Revenue analysis for NONOF.

Quarterly Cost of Revenue

$13.60B
5.49% YoY

As of Mar 31, 2026

Annual Cost of Revenue (TTM)

$59.50B
25.27% YoY

Trailing 12 months ending Mar 31, 2026

Average Cost of Revenue (Comparison Companies)

Cost of Revenue History

Cost of Revenue Comparison

Annual Cost of Revenue Growth Rate (%)

Annual Cost of Revenue Growth (Absolute)